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Enzymatic injectionFibrosis is a common lesion in different pathologic diseases and defined by the excessive accumulation of
collagen. Different approaches have been used to treat different conditions characterized by fibrosis. The
FDA and EMA approved the use of collagenase to treat palmar fibromatosis (Dupuytren’s contracture).
The EMA approved additionally its use in severe Peyronie’s disease, but it has been used off label in other
conditions [1,2]. The approved treatment includes up to three (in palmar fibromatosis) or up to eight (in
penile fibromatosis) injections followed by finger extension or penile modeling procedures, typically
causing severe pain. Frequent single injections are adequate to treat palmar fibromatosis [3]. The need
to repeatedly inject doses of this enzyme can be due to the labile nature of collagenase, which exhibits
a complete activity loss after a short period of time. This study presents a novel strategy to manage this
enzyme based on the synthesis of polymeric nanocapsules that contain collagenase encapsulated within
their matrix. These nanocapsules have been engineered for achieving a gradual release of the encapsu-
lated enzyme for a longer time, which can be up to ten days. The efficacy of these nanocapsules has been
tested in a murine model of local dermal fibrosis, and the results demonstrate a reduction in fibrosis
greater than that with the injection of free enzyme; this type of treatment showed a significant improve-
ment compared to conventional therapy of free collagenase.
Statement of Significance
The use of proteins as therapeutic molecules has recently attracted great interest. Collagenase injection is
the current treatment for fibrotic diseases. Unfortunately, proteins have a low stability and presume sev-
eral repetition cycles to obtain an effective treatment. This article describes a novel treatment for these
types of diseases using collagenase nanocapsules designed to exhibit a sustainable release of the encap-
sulated enzyme, which maintains the enzymatic activity for a long period of time. The therapeutic effect
of nanocapsules was tested in a murine mouse model of local dermal fibrosis, and the results showed an
important improved effect compared to the effect of the administration of free enzyme. These results
indicate a high potential for this novel system to improve the current treatment for fibrotic diseases.
 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
Collagen is the most abundant protein in the body of mammals
(approximately 30% of all proteins) and is a major structural com-
ponent in the extracellular matrix (ECM) [4]. There are different
diseases associated with excess collagen. The overproduction ofcollagen is due to fibroblast hyperproliferation or ECM remodeling
imbalance, among other reasons [5]. The accumulation of this
excess collagen within a tissue can lead to fibrosis, which compro-
mises the tissue function, thereby resulting in physiological disor-
ders and organ malfunction [6,7]. Fibrosis occurs in multiple
conditions. For example, in superficial fibromatosis such as
Dupuytren’s contracture, which consists in formation of a fibrotic
cord in the hand, thus resulting in hand dysfunction. In Peyronie’s
disease, penile involvement includes penile deviation, which
makes sexual relationships difficult or even impossible. Keloidsoi.org/
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autoimmune diseases such as scleroderma characteristically pre-
sent fibrotic/sclerous plaques on localized areas (morphea), gener-
alized on the skin or even systemic (e.g., pulmonary involvement
with lung fibrosis, resulting in high mortality rate).
Fibromatosis has been traditionally treated by surgery to
remove the collagen deposition [6,8]. Unfortunately, surgical pro-
cedures often carry important complications, thereby producing
serious adverse effects in many cases. In addition, the invasive nat-
ure of this type of intervention avoids the general application of
surgical treatments, especially in fragile patients owing to a long
postoperative recovery period [9]. The high prevalence of associ-
ated morbidity in surgical treatments has led to the development
of other types of treatments such as radiotherapy, oral administra-
tion of vitamin E (tocopherol), or injection of corticosteroids,
among others. However, these nonsurgical treatments have not
demonstrated significant improvement in many cases [4,10,11].
The administration of injections of collagenase Clostridium his-
tolyticum (CCH) has emerged as a promising nonsurgical alterna-
tive for the treatment of fibrotic diseases because it is minimally
invasive and cost-effective as well as presents lower complications
and adverse side effects [7,9,12]. CCH is a matrix metalloproteinase
mixture of two synergistic microbial collagenases, AUX-I and AUX-
II, which act in combination and cleave the peptide bond of the col-
lagen fibers between repeated sequences of Glycine–Proline–X (X
being hydroxyproline or proline in the most effective cases) [4].
Collagenase is capable of lysing type 1 and type 3 collagens, which
are the most abundant collagen types in fibrotic diseases. This
enzyme shows a high specificity for collagen fibrils, whereas it
does not produce any remarkable alteration in elastic fibers, vascu-
lar smooth muscle, and axonal myelin sheaths [10]. Thus, this
enzyme has been tested in the treatment of a wide number of
pathologies that course with an abnormal high regulation of for-
mation and/or accumulation of collagen such as intervertebral disc
herniation, [13] vitrectomy, [14] burns, [15] wound healing pro-
cess, keloid, [1,16] and even in the treatment of solid tumors
[17]. In the last application, the intratumoral injection of collage-
nase previous to the treatment with chemotherapeutic agents,
both conventional drugs or nanoparticulated agents, allows a more
homogeneous distribution of these therapeutic compounds along
the tumoral tissue as a consequence of an improved diffusion of
the molecules within a less dense ECM [18].
Owing to its probed effectiveness in some of these pathologies,
CCH has been approved as an enzymatic treatment by the Food and
Drug Administration in the USA in 2 February 2010 and by the
European Agency for the Evaluation of Medicinal Products (EMEA)
in January 2011, and it has been marketed under the name Xiaflex
(Endo Pharmaceuticals, Inc) for the treatment of Dupuytren’s con-
tracture, a palmar fibromatosis [4]; in December 2013, it has been
approved for the treatment of Peyronie’s disease, a fibrosis that
affects the tunica albuginea of the penis [2,19]. Label recommenda-
tions for the treatment of Dupuytren’s contracture include up to
three injections followed by finger extension 24–48 h after injec-
tion, which is usually a painful procedure. However, majority of
the cases need only one injection on the fibrotic lesion [3]. Pey-
ronie’s disease requires up to eight collagenase injections followed
by penile remodeling [20]. The need to apply repeated administra-
tion could be due to the low physico-chemical stability of collage-
nase, which suffers rapid proteolysis when it is exposed to the
proteases present in tissues and also to relatively rapid denatural-
ization by oxidation or hydrolysis, among others. Thus, at physio-
logical pH, collagenase in solution practically lost all its activity
after 24 h, which indicates the labile nature of this macromolecule.
Owing to the short half-life of collagenase, enzymatic activity is
rapidly lost and efficacy is limited. Repeated injections followed
by finger extension or penile remodeling are time consuming andPlease cite this article in press as: M.R. Villegas et al., Collagenase nanocapsules
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events. For example, corporal ruptures of the penis have been
reported to occur relatively frequent five days after the second
injection of each cycle [21].
In view of these data, it is reasonable to think that injecting col-
lagenase with long half-life could increase its efficacy, reduce the
number of injections, spare working time of health professionals,
and decrease the apparition of adverse events. Several alternatives
have been evaluated to prolong the circulation time of these pro-
teins, such as their transport immobilized on the surface of
nanocarriers [22] or their encapsulation within polymeric shells
[17]. However, these types of alternatives do not show a sustained
release of the enzyme for a long time. This study presents a novel
polymeric nanocapsule that contains collagenase encapsulated
inside a matrix and is capable of releasing the enzyme with a con-
trolled kinetics, thereby achieving a prolonged and sustained effect
over time. Moreover, these nanocapsules protect the encapsulated
collagenase against external aggressions, thus maintaining its cat-
alytic activity for a long time. The efficacy of these nanocapsules
has been tested using a mouse model of localized dermal fibrosis
(scleroderma) induced by repeated dermal injection of bleomycin;
these nanocapsules demonstrated a significant reduction in the
fibrotic lesion compared to the conventional administration of free
collagenase. These results could pave the way for the clinical use of
these nanocapsules to treat localized fibrotic diseases. As an addi-
tional advantage, the highly versatile nature of the presented
methodology can be easily applied for the encapsulation of differ-
ent proteins, thus providing interesting alternatives of protein-
based diseases.2. Experimental section
2.1. Materials
Collagenase Type I (Life Technologies); Acrylamide (AA) (Fluka);
2-Aminoethyl methacrylate hydrochloride (Am) (Sigma-Aldrich);
Ethylene glycol dimethacrylate (EG) (Sigma-Aldrich); N,N’-Methy
lenebis(acrylamide) (MBA) (Sigma-Aldrich); Ammonium persul-
fate (AP) (Sigma-Aldrich); N,N,N’,N’-Tetramethylethylenediamine
(TMDA) (Sigma-Aldrich); Amicon Ultra-2 mL Centrifugal Filters
Ultracel 10 K (Millipore); EnChek Gelatinase/Collagenase Assay
Kit (Life Technologies); 10X phosphate-buffered saline (PBS), buf-
fer pH = 7.4 (Ambion).
2.2. Instrumentation section
The hydrodynamic size of protein capsules was measured by
means of a Zetasizer Nano ZS (Malvern Instruments) equipped
with a 633-nm ‘‘red” laser. Analysis using transmission electron
microscopy (TEM) was carried out with a JEOL TEM 3000 instru-
ment operated at 300 kV, equipped with a charge-coupled device
(CCD) camera. Sample preparation was performed by dispersing
these protein capsules in distilled water and subsequent deposi-
tion onto carbon-coated copper grids. A solution of 1% phospho-
tungstic acid (PTA), pH 7.0, was employed as the staining agent
to visualize the protein capsules. Fluorescence was measured using
Synergy 4; power supply for Biotek Laboratory Instrument was
100–240 VAC, 50/60 Hz, and 250 W.
2.3. Synthesis of collagenase nanocapsules
First, the reaction buffer NaHCO3 (0.01 M, pH 8.5) was deoxy-
genated by freeze-vacuum-N2 cycles. Then, collagenase (3.1  10
5 mmol) was dissolved in 1 mL of deoxygenated buffer. AA, Am,
EG, and MBA, the proportions of which are required in each case,: An approach to fibrosis treatment, Acta Biomater. (2018), https://doi.org/
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solution containing monomers was added to the protein solution.
This mixture was stirred at 300 rpm for 10 min under nitrogen
atmosphere at room temperature. Further, 0.013 mmol of AP and
0.02 mmol of TMDA dissolved in 1 mL of the deoxygenated buffer
were added to the mixture. This solution was stirred at 300 rpm for
90 min at room temperature under inert atmosphere. Furthermore,
the encapsulated enzyme was purified by centrifugal separation
with 10-KDa cut-off filters (AMICON Ultra-2 mL 10 KDa) and
washed three times with NaHCO3 buffer (0.01 M, pH 8.5). The cap-
sules of collagenase were preserved at 4 C.2.4. Enzymatic activity assay
The samples were incubated using the same collagenase con-
centration (measured by absorbance at 280 nm) in PBS with phys-
iological pH = 7.4 and at 37 C under stirring. The encapsulation
process does not affect the absorbance because the monomers
and polymers created do not have absorbance at this wavelength.
At certain times, an aliquot of this solution was removed and its
enzymatic activity was evaluated using the commercial kit
(EnzChekGelatinase/Collagenase Assay Kit). The kit provides a flu-
orimetric method, and its protocol consists in mixing the collage-
nase sample with commercial buffer, which contains calcium and
fluorescent-labeled gelatin. The fluorescence signal is quenched
until gelatin digestion. Then, the enzymatic activity of the collage-
nase sample was determined by fluorescence release.2.5. Hydrolysis assay
Collagenase nanocapsules were incubated in PBS with physio-
logical pH = 7.4 and at 37 C under stirring. At certain times, an ali-
quot was removed from the solution and stained with 1%
phosphotungstic acid; these nanocapsules were then observed by
TEM.2.6. Mouse model of scleroderma
Female 6-week-old C3H/HeNHse mice were purchased from
Envigo (Valencia, Spain). Dermal fibrosis was induced by subcuta-
neous injections of 100 lg of bleomycin (1 mgml-1; Mylan Phar-
maceuticals, Barcelona, Spain) or 0.9% saline control into the
shaved skin at the back every day for 4 weeks as previously
described [23]. To analyze the effect of collagenase administration
in this model after fibrosis induction, 10 mice in each group were
administered with 300 mg of collagenase (Life Technologies), either
as a single subcutaneous injection of free collagenase or encapsu-
lated nanocapsules, in the bleomycin-injected skin area and main-
tained for 10 days. To ensure that the amount of injected free and
encapsulated collagenase is the same, the total protein content was
determined by absorbance at 280 nm. The study was approved by
Animal Care and Use Committee of Hospital 12 de Octubre with
protocol reference number PROEX 407/15, and this was carried
out in accordance with the institutional guidelines.
The treated skin was harvested, and paraffin was embedded for
histological evaluation of the collagen dermal area by using the
Masson’s trichrome staining kit (Sigma-Aldrich, St. Louis, USA).
Masson-stained full-thickness skin sections were photographed
and digitalized using an AxioCam ERc 5S camera and ZEN lite
2012 software (Zeiss, Jena, Germany). The blue-stained collagen
fractional area was quantified using ImageJ software (http://rsb.
info.nih.gov/ij). The collagen area of each individual mouse was
calculated as the mean area of several (three to five) sections of
the central part of the excised skin piece.Please cite this article in press as: M.R. Villegas et al., Collagenase nanocapsules
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Data were analyzed using Prism software (GraphPad Software,
San Diego, CA, USA). Results are expressed as mean ± standard
deviation (SD), and quantitative data were analyzed by the
Mann–Whitney U test. P values < 0.05 were considered significant.3. Results and discussion
In this work, a protective polymer capsule is designed around
the collagenase whose function is to release the encapsulated
enzyme in a controlled sustained manner for a long period of time.
In this way, the polymeric nanocapsule acts as collagenase reser-
voir that presents a slow and tunable kinetic release capable of
providing a prolonged effect, thus avoiding the need for important
and repeat doses.
Protein nanocapsules have been widely studied to obtain a con-
trollable delivery system that also protects the cargo at the same
time. In this sense, the development of a protein carrier based in
its encapsulation within the polymeric mesh has received increas-
ing attention in the last few years [24]. This type of system has
demonstrated its capacity to trigger the protein release in response
to different stimuli, for example, enzymes present in the target site,
according to local environment or specific cellular events [25]. In
addition, these protein nanocapsules have been designed to
achieve a sequential release of multiple proteins, so that the
release of the first protein triggers the release of the rest in a tan-
dem sequence [26]. As an added value, polymeric nanocapsules act
as a protective coating for the encapsulated enzyme against exter-
nal stresses that can compromise its structure and, therefore, its
catalytic activity [17].
Thus, with the objective to obtain a collagenase nanocapsule
that provides a sustained release, a polymeric mesh was designed
to coat the protein. Our nanocapsules have been synthesized by
free radical polymerization of two types of monomers, i.e., a neu-
tral monomer, AA, and Am. AA is widely used as a structural mono-
mer, whereas Am presents the capacity to adsorb around negative
proteins by electrostatic affinity owing to its positive charge in the
aqueous phase. Thus, the enrichment of monomers around the pro-
teins is favored by electrostatic bonding. Additionally, once the
nanocapsule is formed, the presence of these amino groups on
the surface avoids capsule aggregation by repulsion charge,
thereby enhancing the colloidal stability of the system. Finally,
EG was chosen as a degradable crosslinker to form the polymeric
shell [27].
First, the monomers and protein are allowed to come in contact
in an aqueous solution free of oxygen. The protein and monomer
mixture was kept under stirring for 10 min to allow the adsorption
of the monomers on the negative surface of protein through inter-
molecular interactions. Then the protein surface could be enriched
with monomers in such a way that the polymerization occurs
around the protein. Oxygen, which can terminate the radical poly-
merization process, is removed from the buffer reaction previous
to the addition of radical initiators. This first stage is followed by
a polymerization step. The polymerization is initiated by the addi-
tion of AP in the presence of TMDA, and this forms free radicals of
oxygen in the aqueous solution at room temperature through a
basic catalysis mechanism. AP is the initiator of free radical gener-
ation and this is catalyzed by TMDA, which promotes the decom-
position of AP into free radicals, thereby decreasing the
activation energy of polymerization [28]. In this way, the addition
of TMDA allows the free radical polymerization process to occur at
room temperature. The free radical process leads to polymerization
of acryloyl groups of monomers and crosslinker, thus yielding a
polymeric mesh that coats the protein (Scheme 1). The mixture: An approach to fibrosis treatment, Acta Biomater. (2018), https://doi.org/
Scheme 1. Synthesis of collagenase nanocapsule by free radical polymerization. AA, Am, EG, PA/TMDA are referred to acrylamide, 2-Aminoethylmethacrylate hydrochloride,
ethylene glycol dimethacrylate, ammonium persulfate/ N, N, N0 , N0 , tetramethylenediamine respectively.
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nanocapsules were isolated by centrifugal separation with 10-
KDa cut-off filters to remove the excess monomer. Collagenase acts
on large substrates (collagen fibers), and therefore, it is necessary
to consider its release to facilitate its catalytic activity. To provide
a controlled release mechanism, EG was chosen as a pH-responsive
crosslinker. Thus, the obtained nanocapsules would be degradable
by hydrolysis. The collagenase release mechanism is shown in
Scheme 2. In the aqueous medium, water molecules act as nucle-
ophiles that attack the carbonyl group of the crosslinker, which
results in the hydrolysis of the ester bonds. This crosslinker degra-
dation is catalyzed in acidic environments because of an interac-
tion of protons with the oxygen atom of the carbonyl group, thus
increasing the polarity of the covalent bond and favoring the nucle-
ophilic attack by water.
3.1. Optimization of collagenase synthesis for sustained release
3.1.1. Previous work
Our research group recently reported the encapsulation of col-
lagenase inside degradable polymeric nanocapsules using a
protein-to-monomer ratio of 1:2025 and AA-to-Am-to-EG mono-
mer ratio of 7:6:2 [17]. These conditions favored the nanocapsules
to release the encapsulated enzyme in <12 h under physiological
conditions. This presumes a high improvement in the stability of
the enzyme, and this relatively rapid release is suitable for certainPlease cite this article in press as: M.R. Villegas et al., Collagenase nanocapsules
10.1016/j.actbio.2018.05.007clinical applications such as in the case of fibrotic disease, a longer
release time is required as mentioned.
3.1.2. Strategies to achieve a sustained and prolonged release
Based on the previous work, different strategies have been per-
formed to achieve a prolonged and sustained release. In this way, it
is hoped that the collagenase nanocapsules can act a depot of the
proteolytic enzyme and improve the temporal window by enhanc-
ing its therapeutic effect. Two strategies were developed to achieve
this goal; first, the degradable crosslinker ratio was reduced to
reduce the hydrolyzable attack points in the polymeric mesh,
and second, obtaining collagenase nanocapsules with sustained
release was addressed from another point of view, that is, the addi-
tion of an additional nondegradable crosslinker; in this way, the
polymeric mesh would become more robust and the collagenase
release rate would decrease.
3.1.2.1. Decrease in the proportion of degradable crosslinker. To
decrease the hydrolysis rate of the collagenase nanocapsules, the
amount of degradable crosslinker was reduced to half with regard
to a previous work [17]. The protein-to-monomer ratio was main-
tained constant because a significant alteration in this ratio can
lead to poor protein encapsulation. The capacity to provide a sus-
tained enzymatic activity of these nanocapsules for a long time
was evaluated by incubating the nanocapsules in an aqueous solu-
tion at physiological pH and temperature under orbitalic soft stir-: An approach to fibrosis treatment, Acta Biomater. (2018), https://doi.org/
Scheme 2. Degradation mechanism of the collagense nanocapsules.
M.R. Villegas et al. / Acta Biomaterialia xxx (2018) xxx–xxx 5ring. Then, at certain times, an aliquot of this solution was
removed, and the enzymatic activity was measured using a com-
mercial kit protocol. The nanocapsules retain more than 50% of
the catalytic capacity initially for 2 days, which is a significantFig. 1. (a) Study of Dynamic Light Scaterring (DLS) of collagenase nanocapsules with dif
ratios AA/Am (purple). Micrograph by transmission Electron Microscopy (b) AA/Am/
correspond to 100 nm). Study of free collagenase was represented in blue.
Please cite this article in press as: M.R. Villegas et al., Collagenase nanocapsules
10.1016/j.actbio.2018.05.007improvement compared to the free enzyme, which lost more than
80% of its capacity after 1 day. The encapsulation efficacy is also
dependent on the capacity of the monomers to get adsorbed on
the protein surface, and this capacity is related to the intermolec-ferent AA/Am ratios. Study of stability of collagenase nanocapusules with different
EG = 7.5/6.5/1, (c) AA/Am/EG = 7/7/1 and (d) AA/Am/EG = 8/6/1 (white scale bar
: An approach to fibrosis treatment, Acta Biomater. (2018), https://doi.org/
6 M.R. Villegas et al. / Acta Biomaterialia xxx (2018) xxx–xxxular interactions between both systems. To evaluate whether the
AA-to-Am monomer ratio could play a role in this process, two
different monomer ratios were also evaluated, i.e., AA-to-Am-to-
EG ratios of 7:7:1 and 8:6:1, respectively. Neither of these cases
provided a significant improvement in the catalytic activity during
time, thus losing more than 50% of their capacity after 2 days, sim-
ilar to the results of the previous work (Fig. 1).
The presence of a crosslinker is strictly needed to obtain a dense
and protective mesh around the protein. Although a high decrease
in the crosslinker ratio could be an option to extend the release
time, it could result in an inappropriate capsule formation. For this
reason, the possibility to reduce its amount even more was dis-
carded and the other strategy was addressed.
3.1.2.2. Introduction of a nondegradable crosslinker. Instead of
reducing the crosslinker ratio, a novel strategy that consists in
the introduction of an additional nondegradable crosslinker,
MBA, was employed. The introduction of this crosslinker should
not alter the nanocapsule formation because the crosslinker-to-
monomer ratio was maintained and could increase the degradation
time of the nanocapsule, thus allowing a sustained release for a
longer time. Although the addition of a nondegradable crosslinker
can result in incomplete collagenase release, this strategy
decreases the hydrolyzable points in the polymeric mesh without
altering the crosslinker ratio. Thus, with the protein-to-monomer
ratio as 1:2025 and AA-to-Am-to-crosslinker ratio as 7:6:2, which
provided a good encapsulation capacity, different ratios of both
degradable and nondegradable crosslinkers were studied. The
addition of the new crosslinker did not alter the size and morphol-
ogy of the nanocapsules in all cases. The results indicate thatFig. 2. (a) Study of Dynamic Light Scaterring (DLS) of collagenase nanocapsules with dif
ratios EG/MBA (purple). Micrograph by transmission Electron Microscopy (b) AA/Am/EG
1.5 (white scale bars correspond to 100 nm). Study of free collagenase was represented
Please cite this article in press as: M.R. Villegas et al., Collagenase nanocapsules
10.1016/j.actbio.2018.05.007employing a 1:1 ratio of degradable and nondegradable crosslink-
ers enables the system to maintain the enzymatic activity for a
really long time. This sample shows a sustained release of around
50% of its initial activity lasting for 10 days and maintaining 15% of
its activity for 12 days (Fig. 2). Surprisingly, for unknown reasons,
when different ratios of the two crosslinkers are employed, the
capacity to maintain the catalytic activity reduces to values even
lower than those of the previous systems that carry only the
degradable crosslinker, i.e., when the nondegradable crosslinker
is employed both in a higher ratio and in a lower ratio. In any case,
the system that employs a 1:1 ratio exhibits excellent properties.
The hydrolysis of this sample was observed in the micrographs
obtained by TEM (Fig. 3). It can be observed that the collagenase
nanocapsules progressively lost their integrity as is expected
because they are degradable nanocapsules. Owing to their sus-
tained release, a sample with an EG-to-MBA ratio as 1:1 was cho-
sen for in vivo evaluation in comparison with the current
treatment.
Therefore, two strategies were evaluated to achieve a sustained
and prolonged release of collagenase. Both approaches demon-
strated an increase in the collagenase release time with regard to
our previous work. In the first study, a decrease in degradable
crosslinker ratio in the synthesis of collagenase nanocapsules
was evaluated. This strategy was based on the idea that decreasing
the degradable crosslinker ratio led to a reduction in the hydrolyz-
able attack points. Although the stability of the collagenase
nanocapsules was higher than that of the free enzyme, the results
were not satisfactory because the collagenase release was not
sustained, losing almost completely the enzymatic activity after
3 days. The idea to continue reducing the crosslinker ratio was dis-ferent EG/MBA ratios. Study of stability of collagenase nanocpasules with different
/MBA = 7/6/1/1, (c) AA/Am/EG/MBA = 7/6/1.5/0.5 and (d) AA/Am/EG/MBA = 7/6/0.5/
in blue.
: An approach to fibrosis treatment, Acta Biomater. (2018), https://doi.org/
Fig. 3. TEM micrographs of collagenase nanocapsules incubated at physiological conditions at different times.
M.R. Villegas et al. / Acta Biomaterialia xxx (2018) xxx–xxx 7carded because the presence of crosslinker is necessary to obtain a
robust polymeric coating. Thus, the problem was addressed from
the other point of view, by the introduction of an additional
nondegradable crosslinker. Despite the fact that the addition of a
nondegradable crosslinker presented a potential liability regarding
the possibility to lead to an incomplete collagenase release, it
decreased the hydrolysis-sensitive points in the nanocapsules
without altering the crosslinker ratio. This approach yielded the
nanocapsules with excellent properties for the treatment of fibrotic
lesions because they exhibited a sustained and prolonged collage-
nase release for up to 10 days. Once the synthetic conditions for
the formation of collagenase nanocapsules with desired properties
are optimized, the suitability to treat fibrotic lesions with this nan-
odevice was evaluated in a mice model as proof of concept in com-
parison with the conventional free enzyme administration.3.2. In vivo cytotoxicity test of collagenase nanocapsules
To check the biocompatibility of the collagenases nanocapsules
in vivo, a fixed amount of nanocapsules or free collagenase wasFig 4. Study of biocompatibility of nanocapsules. Mice received a single subcutaneous in
Masson’s trichrome (collagen fibers are stained in blue). Data are representative of one
Please cite this article in press as: M.R. Villegas et al., Collagenase nanocapsules
10.1016/j.actbio.2018.05.007injected subcutaneously into the shaved skin at the back of healthy
mice. After 10 days, the animals were sacrificed and histological
analysis of collagenase-injected skin showed a normal structure
of all skin layers and absence of inflammatory cell infiltration
(Fig. 4). Dermal collagen area and structure did not show changes
compared to the normal (uninjected) skin (Normal skin vs. free col-
lagenase, p = 0.7; normal skin vs. nanocapsules, p = 0.99; and free
collagenase vs. nanocapsules, p = 0.628).3.3. In vivo evaluation of the efficacy of collagenase nanocapsules
To study the efficacy of collagenase nanocapsules on
bleomycin-induced skin fibrosis, we evaluated changes in the
fibrotic area induced by bleomycin for 4 weeks, after injection of
either free collagenase or collagenase nanocapsules. We found a
marked increase in the dermal collagen area of the dermis after
bleomycin injection compared to control (saline-injected) group
(Fig. 5).
The fibrotic area, evaluated as the fractional collagen-stained
area (blue-stained area) of the dermis, was significantly reducedjection with a fixed amount of nanocapsules or free collagenase. Skin was stained by
experiment with three-four mice per group. Bar 50 mm.
: An approach to fibrosis treatment, Acta Biomater. (2018), https://doi.org/
Fig 5. Effect of collagenase nanocapsules in bleomycin induced skin fibrosis. C3H mice received daily subcutaneous injections of bleomycin and were treated with free
collagenase or nanocapsules. Control mice were daily injected with saline. Fibrosis was quantified as the collagen area (blue-stained area as stained by Masson trichrome),
expressed as a fraction of the total skin area. Data are representative of two independent experiments with 10 mice per group. Bar 50 mm.
8 M.R. Villegas et al. / Acta Biomaterialia xxx (2018) xxx–xxxbleomycin-injected, collagenase nanocapsule–treated mice com-
pared to those in bleomycin-injected mice (p < 0.0001) and
bleomycin-injected, free collagenase–treated mice (p = 0.026).
There were no significant differences between bleomycin-
injected, free collagenase–treated and bleomycin-injected groups
(p = 0.457; Fig. 5). Therefore, administration of a single dose of
encapsulated collagenase nanocapsules significantly decreased
the collagen area, whereas the same dose of collagenase without
encapsulation (free collagenase) was insufficient to reduce the col-
lagen area.
The fact that a single injection of collagenase nanocapsules
results in a significant decrease in the collagen area with regard
to free enzyme could presume an important advance the treatment
for fibrotic lesions. In the future, preclinical studies should be orga-
nized to conduct clinical trials in humans.4. Conclusion
This study presents a novel collagenase nanocapsule capable of
a sustained release and delivery of the proteolytic enzyme. These
collagenase nanocapsules were designed to protect the activity of
the collagenase enzyme and release with controllable kinetics for
long and modular periods of time. These polymeric nanocapsules
presume a delivery system of collagenase capable of releasing
the enzyme under physiological conditions for 10 days.
This type of release is highly beneficial in enzymatic treatments
because a prolonged effect of the required enzyme over time is
obtained, thus allowing the use of lower doses and/or reducing
the number of injections necessary to achieve acceptable results.
The high stability conferred by this coating composition coupled
with the sustained release profile results in a promising advance
in the stabilization of the enzyme and makes it possible to improve
the current clinical treatment. It has been observed in fibrotic mod-Please cite this article in press as: M.R. Villegas et al., Collagenase nanocapsules
10.1016/j.actbio.2018.05.007els that the encapsulated collagenase showed a high efficacy of
degradation compared to that of free enzyme, which is the actual
treatment. The application of this strategy would pave way for
the proteins to get delivered in a more sustained release, which
would provide an important advance in their clinical applications.
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